TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
Study findings on tuberculosis are outlined in reports from AstraZeneca
October 28th, 2008
"The aim of this study was to determine the in vitro activity of lipiarmycin against drug-resistant strains of Mycobacterium tuberculosis (MTB) and to establish the resistance mechanism of MTB against lipiarmycin using genetic approaches. MIC values were measured against a panel of drug-resistant strains of MTB using the broth microdilution method," scientists in Bangalore, India report. "Spontaneous lipiarmycin-resistant mutants of MTB were tested for cross-resistance to standard anti-TB drugs, and their rpoB and rpoC genes were sequenced to identify mutations. Lipiarmycin exhibited excellent inhibitory activity against multidrug-resistant strains of MTB with MIC...
Source: TB & Outbreaks Week (2008-10-28)
|
